Introduction: Despite increased visibility of clinical trials through international trial registries, patients often remain uninformed of their existence, especially if they do not have access to adequate information about clinical research, including the language of the information. The aim of this study was to describe the context for transparency of clinical trials in Croatia in relation to countries in Central and Eastern Europe, and to assess how informed Croatian patients are about clinical trials and their accessibility.
Introduction
Transparency is at the heart of health research (1) . Transparency and completeness of clinical trial reporting is important not only for unbiased assessment of health interventions and formulation of health practice guidelines, but is also an obligation towards altruistic individuals who volunteer for research (2, 3) . The increase in the transparency standards for clinical trials that we witness today, from the availability of information about the existence of trials to the availability of trial results and data, is the outcome of joined effort of journal editors, researchers and policy makers to improve the quality of health research and empower the patients and their families to get the best treatment available (3-6).
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Despite the increased openness of information of clinical trials, it is still often difficult to successfully enrol participants into trials. Although most patients seem to be aware and willing to participate in clinical trials, only a small fraction of patients who meet the requirements actually participate in trials (7, 8) . Only 27% of patients discuss clinical trials as an option with their physician (9) . There is also evidence of gender imbalance in the awareness about clinical trials, with male patients reporting more often that they are informed about clinical trials (10) .
One of the main reasons why patients take part in clinical trials is the possibility to benefit from a new treatment (3, 11) . On the other hand, there are many potential reasons why patients avoid entering a clinical trial. These include the fear of being a "human guinea pig", trying something no one knows whether it would work, worries that they will be in the control group receiving a placebo and be thus left without help, as well as the feeling that joining a clinical trial means that all hope is lost (12) . One of the problems contributing to this distrust is the lack of understanding of the methodology of clinical trials and their purpose, despite the information received during informed consent procedure (11) . More active engagement in information translation to patients may be beneficial, as studies show that engagement of special educators, who spend more time talking face to face with participants, improve participants' understanding of specific clinical trial (13) . Also, new forms of recruitment strategies may bring down some barriers to patient participation in clinical trial (14) . However, there is also evidence that education interventions related to participation in clinical trials may not influence the patients' motivation for trial accrual (15) .
Patients' knowledge and awareness of and participation in clinical trials may be a special problem for smaller research communities such as Croatia.
There is little information on how well patients are informed about clinical trials in Croatia (16) . Judging from the experience of low awareness of and adherence to common medical procedures among Croatian patients (17, 18) 
Materials and methods

Study design
Statistical analysis
Categorical data were presented as percentages or ratios (when N < 100) and continuous data as median ± interquartile range. the SPSS version 18 (SPSS Inc., Chicago, IL). The significance threshold was set at P < 0.05 (for posthoc tests, Bonferroni adjustment was made and significance threshold was set at P < 0.01).
Results
Context for trial registration in Croatia
The conduct of clinical trials in Croatia is governed by several laws and regulations (20) . Clinical trials, both industry and non-industry sponsored, on drugs and medical devices must be approved by the Minister of Health, after positive approval from the national CEC. Trials involving other interventions, which are outside of the scope of the CEC, must be approved by relevant local ethics committees. There is no national policy on the registration of clinical trials before their inception, but there is legal requirement for a register of all approved clinical trials since 2010 (20) . However, the scope of this register is not yet defined and it has not been established, as judged by the information from the web-site of the Ministry (January 2017). 
Patients' survey
During the sampling time-frame, responses from 257 participants were collected (Table 3) . We could not calculate the response rate due to the open nature of the survey, including open call to patients via their respective social media groups. There were 117 men (46%) and 137 women (53%), mostly in the 41 -80 age group (67%). Patients were treated for their major chronic disease or cancer in Split (69%), Zagreb (25%) or Osijek (2%).
The treatment was mostly received in university hospital centres (67%) and in family medicine practices (40%). Patients reported different chronic conditions and most common diagnosis were carcinomas (26%), diabetes (13%) and mental illnesses (12%). Members of patients' associations constituted 21% of the respondents.
Although 82% participants reported that they felt free to ask their physicians about their treatment, 69% of those were actually interested in asking their physician and/or did ask (Table 4) . Even when they asked, 20% did not understand or did not fully understand the information they got from their physician. Although patients reported good communication with their physicians, a half of the respondents searched for more information, mostly from friends (33%) or the Internet (41%), predominantly using general searches rather than specialized health sites. Only 2% of the respondents were Although 66% of the respondents were aware of clinical trials, only 15% were informed about possibilities of participating in a trial (Table 5) . Furthermore, 58% of the respondents were willing to try new treatments but only 6% actually participated in a clinical trial. Men significantly more often reported being informed about clinical trials than women (63% vs. 37%, P = 0.017).
Survey respondents coming from different patients' groups significantly differed in their answers ( Table 6) . As expected, patients attending the hospital oncology department reported having significantly more annual appointments with the physician(s) than other respondent groups (P < 0.001). Respondents from the online survey and those from patients' associations reported more often that they were aware of clinical trials in comparison to other groups (P < 0.001). Online survey respondents also more often reported the willingness to try new treatments that the other groups, except the respondents from patients' organizations (P = 0.014).
Discussion
Our study showed that Croatian patients were not well informed about possibilities of participating in a clinical trial. Although they were reportedly aware of existence of trials, they did not take the opportunity to participate in them. Only 12% of the patients reported to be informed about clinical trials by their physicians, which is much lower than current percentages reported elsewhere in EU, such as 27% in England and Scotland (9) . Men in our study, similar to the study in the UK more often reported knowledge of clinical trials, although women significantly more often used the Internet to search for health information, as has been shown for other patient populations (9, 24) .
The results of our survey should be interpreted with caution because of the methodological constraints of the convenient survey sample and selfreported nature of the answers. The survey was performed in a single university hospital centre and two family medicine practices in south Croatia, as well as on a national, albeit small sample of members from patients' organizations, and cannot be fully representative of the whole Croatia. The sample may have been biased towards patients treated in larger cities in Croatia, as over 90% of the respondents were treated in two largest hospital settings -Zagreb and Split. However, this means that the observed low level of engagement in or information on clinical trials in such a sample may be an underestimation of the situation at the national level, and may be even lower in rural areas. Our study is, to the best of our knowledge, the first published survey of patients' awareness and participation in clinical trials in Croatia, and should be taken as the baseline evidence for any future actions and interventions to increase the knowledge and participation in clinical trials. According to our analysis of information on trials available in major international registries, Croatian patients can learn most about potentially relevant clinical trial from ClinicalTrials.gov then from any other, including the EUCTR. In general, ClinicalTrials.gov has more registered studies from the countries analysed in our study than the EUCTR, mostly because the scope of the two registers is different and the US register is older than the EUCTR (5,6). EUCTR, which Croatia officially joined in 2013, still has the fewest number of registered trials from Croatia, especially those with already available results. Unfortunately, almost all of the information in EUCTR is not in Croatian, and all information in the ClinicalTrials.gov is in English.
In conclusion, despite increased transparency of clinical trials worldwide, Croatian patients still have limited access to full information about clinical trials performed in Croatia, particularly in their own language and have low awareness about clinical trials and the possibilities of participating in them is rather low, despite reported availability of Internet resources and good communication with their physicians. The first step in increasing this transparency for the benefit of the patients would be to fully implement legal provisions that have existed for more than five years (20) . Only when the basic information about clinical trials is full, transparent and easily accessible, preferably in native language, efforts could be focused on managing the communication with patients (14), with physicians and other health workers to support participation in clinical trials and clear insecurities with participants (27) .
